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Abstract
Background: Retrospective observational studies suggest that transmission of Trypanosoma cruzi does not occur in
treated women when pregnant later in life. The level of parasitemia is a known risk factor for congenital
transmission. Benznidazole (BZN) is the drug of choice for preconceptional treatment to reduce parasitic load.
The fear of treatment-related side effects limits the implementation of the Argentine guideline recommending BZN
60d/300 mg (or equivalent) treatment of T. cruzi seropositive women during the postpartum period to prevent
transmission in a future pregnancy. A short and low dose BZN treatment might reduce major side effects and
increase compliance, but its efficacy to reduce T. cruzi parasitic load compared to the standard 60d/300 mg course
is not yet established. Clinical trials testing alternative BZN courses among women of reproductive age are urgently
needed.
Methods and design: We are proposing to perform a double-blinded, non-inferiority randomized controlled trial
comparing a short low dose 30-day treatment with BZN 150 mg/day (30d/150 mg) vs. BZN 60d/300 mg. We will
recruit not previously treated T. cruzi seropositive women with a live birth during the postpartum period in
Argentina, randomize them at 6 months postpartum, and follow them up with the following specific aims:
Specific aim 1: to measure the effect of BZN 30d/150 mg compared to 60d/300 mg preconceptional treatment on
parasitic load measured by the frequency of positive Polymerase Chain Reaction (PCR) (primary outcome) and by
real-time quantitative PCR (qPCR), immediately and 10 months after treatment.
Specific aim 2: to measure the frequency of serious adverse events and/or any adverse event leading to treatment
(Continued on next page)
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: mcafferata@iecs.org.ar
1Instituto de Efectividad Clinica y Sanitaria (IECS), Buenos Aires, Argentina
2Unidad de Investigación Clínica y Epidemiológica Montevideo (UNICEM),
Montevideo, Uruguay
Full list of author information is available at the end of the article
Cafferata et al. Reproductive Health          (2020) 17:128 
https://doi.org/10.1186/s12978-020-00972-1
(Continued from previous page)
interruption.
Trial registration: ClinicalTrials.gov. Identifier: NCT03672487. Registered 14 September 2018
Keywords: Benznidazole, Chagas disease, Preconception care, Randomized controlled trial, Trypanosoma cruzi
Resumen (Spanish)
Antecedentes: Estudios observacionales retrospectivos sugieren que la transmisión del Trypanosoma cruzi no
ocurre en mujeres tratadas cuando quedan embarazadas más adelante. La carga parasitaria en la sangre es un
factor de riesgo conocido para la transmisión congénita. El Benznidazol (BZN) es el fármaco de elección para el
tratamiento preconcepcional de la mujer en edad fértil para reducir la carga parasitaria.
El temor a los efectos adversos relacionados con el tratamiento limita la implementación de la Guía Argentina que
recomienda el tratamiento con BZN 60d/300 mg (o equivalente) en mujeres seropositivas a T. cruzi durante el
período posparto para prevenir la transmisión en un futuro embarazo. Un tratamiento más corto y con una dosis
menor de BZN podría reducir los eventos adversos y mejorar la adherencia al mismo, pero aún no se ha
establecido su eficacia para reducir la carga parasitaria de T. cruzi en comparación con el esquema estándar de 60d/
300 mg. Se necesitan con urgencia ensayos clínicos que prueben esquemas alternativos de BZN en mujeres en
edad reproductiva.
Métodos y diseño: Estamos proponiendo realizar un ensayo clínico controlado aleatorizado doble ciego de no
inferioridad que compara un tratamiento corto de 30 días a dosis bajas con BZN 150 mg/día (30d/150 mg) versus
BZN 60d/300 mg. Se reclutarán mujeres seropositivas para infección por T. cruzi no tratadas previamente, que hayan
tenido un nacido vivo, durante el periodo de posparto en Argentina. Las mujeres serán aleatorizadas a los seis
meses posparto y serán seguidas, con los siguientes objetivos específicos:
Objetivo específico 1: evaluar el efecto del tratamiento preconcepcional con BZN 30d/150 mg comparado con BZN
60d/300 mg por medio de la carga parasitaria, medida por la frecuencia de PCR positiva (resultado primario) y PCR
cuantitativa a tiempo real (qPCR), al final del tratamiento y a los 10 meses post tratamiento.
Objetivo específico 2: medir la frecuencia de eventos adversos serios y/o cualquier otro evento adverso que
conduzcan a la interrupción del tratamiento con BZN 30d / 150 mg en comparación con BZN 60d/300 mg.
Palabras clave: Benznidazol, Enfermedad de Chagas, Cuidado preconcepcional, Ensayo clínico controlado
aleatorizado, Trypanosoma cruzi
Plain English Summary
Chagas disease is caused by the parasite Trypanosoma
cruzi. The chronic disease can last for decades and is a
major cause of heart disease in the Americas. Around 6
million persons are currently infected, including 1 million
women of reproductive age. Despite it is transmitted by a
blood-sucking bug, a growing number of newborns get
the infection from their mothers during pregnancy or
birth (congenital transmission), and infected babies are at
risk of developing chronic Chagas disease later in life.
Previous studies suggest that women treated at a
young age achieve a long-lasting reduction of blood
levels of the parasite and therefore do not transmit Try-
panosoma cruzi when pregnant later in life. But doctors
and patients are reluctant to prescribe or take the treat-
ment of choice to prevent transmission in a future preg-
nancy, benznidazole 300 mg for 60 days, because they
are afraid of side effects.
In this study, we propose to compare the standard
treatment with an alternative one which reduces by 50%
the dose and duration of treatment: 150 mg of benznida-
zole for 30 days. We will recruit women carrying the
parasite in Argentina, not previously treated, with a live
newborn. Six months after the delivery, they will be
assigned by chance to either receive low-dose treatment
or the standard one. Then, they will be followed up for a
year to evaluate side effects, compliance to treatment
and the amount of the parasite in the blood.
We have the expectation that the new alternative
course will not be less effective than the conventional
one, while diminishing side effects and costs.
Introduction
Statement of the problem
Chagas disease, or American trypanosomiasis, is caused
by the protozoan parasite Trypanosoma cruzi. It is a
major cause of cardiac disease in the Americas. An esti-
mated 6 million persons are currently infected, including
1 million women of reproductive age [1]. In the U.S., the
estimated number of T. cruzi-infected women of
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reproductive age was 130,522 in 2000 [2]. Mothers can
transmit T. cruzi to their babies during pregnancy, and
infected babies are at risk of developing chronic Chagas
disease later in life [3]. Our meta-analysis of published
data showed a 5.0% congenital transmission rate in en-
demic countries [4]. There is a risk of pregnancy compli-
cations, including preterm premature rupture of
membranes and preterm delivery. T. cruzi-infected new-
borns may have severe morbidity and are at risk of Neo-
natal Intensive Care Unit (NICU) hospitalization and
neonatal mortality [5]. Available drugs are not approved
for use during pregnancy. Asymptomatic infected new-
borns can be effectively treated if detected early, but a
follow-up to at least 8 months of age is needed in most
cases to diagnose congenital transmission by measuring
persisting antibodies [6]. Losses to follow-up are fre-
quent, and many infected infants remain untreated.
There is thus an urgent need to prevent congenital
transmission of T. cruzi.
Background
Studies and current recommendations on treatment to
prevent congenital transmission
Retrospective observational studies suggest that trans-
mission of the Trypanosoma cruzi does not occur in
treated women when pregnant later in life [7–9]. The
level of parasitemia is a known risk factor for congenital
transmission [5, 10–12]. Two retrospective observational
studies suggested that women treated at a young age do
not transmit T. cruzi when pregnant later in life [7, 9].
The first study included 32 children born to 16 women
who were treated with BZN when they were six to 15
years old and who were evaluated 14 years later. None of
the children were infected [9]. A more recent and larger
observational study compared women treated before
pregnancy to untreated women. On average, women
were treated 17 years before follow-up. Among the 222
children born to untreated women, 34 were infected
with T. cruzi (15.3%), while no infection was found
among the 132 children of previously treated women [7].
Another small observational study found no congenital
transmission among 15 women who became pregnant
from one to 8 years after treatment [8].
We found no published or ongoing randomized con-
trolled trials evaluating preconceptional etiological treat-
ment of women infected with T. cruzi to prevent
congenital transmission.
Despite the limited observational evidence and the lack
of experimental studies, experts recommend or strongly
suggest that T. cruzi seropositive women of reproductive
age should be treated to prevent congenital transmission
in future pregnancies [9, 13]. In Argentina, the national
guideline recommends the treatment of T. cruzi sero-
positive women during the postpartum period with
either BZN or Nifurtimox, with a preference for BZN
due to the high frequency of side effects of Nifurtimox
[14].
Drug of choice for preconceptional treatment
BZN is the recommended trypanocidal drug for the pre-
vention of congenital transmission. A Cochrane system-
atic review summarized the studies that evaluated the
effects of trypanocidal drugs on parasite-related and pa-
tient outcomes [15]. BZN is the drug that was studied
the most. Furthermore, the observational studies show-
ing a potential preventive effect on congenital transmis-
sion evaluated BZN.
Randomized controlled trials on BZN
The Cochrane review summarized four randomized con-
trolled trials (RCTs), none of which were performed
among women of reproductive age with PCR as an out-
come [15]. Treatment with BZN showed between a 50
and 88% statistically significant reduction in parasite-
related outcomes (e.g., positive serology, PCR).
Two additional trials were recently published. The
CHAGASAZOL trial compared 60 days of BZN to posa-
conazole, and the intention-to-treat analysis showed
38.4% treatment failure measured by PCR in the BZN
group vs. more than 80% treatment failure in the posa-
conazole groups [16]. The mean age of the CHAGASA-
ZOL trial subjects in the BZN group was 40. The
BENEFIT trial compared BZN vs. placebo among pa-
tients with Chagas’ cardiomyopathy [17]. The mean age
of the subjects was 55 years. Positive conventional PCR
was 60.5% at baseline, and the rate of conversion to
negative PCR was 66.2% in the BZN group vs. 33.5% in
the placebo group. In the Argentina and Bolivia sites,
conversion rates to a negative PCR were 73.0% in the
BZN group and 28.6% in the placebo group. There was
no effect on the complications of cardiomyopathy. The
BENEFIT trial is the largest placebo-controlled random-
ized trial performed thus far.
The comparison of treatment effects observed in trials
in adults compared to those in children [15, 17] and ob-
servational evidence [7, 18] suggest that the therapeutic
response to BZN treatment may be better and stronger
in young and healthy subjects than in older subjects with
organ compromise, like those who participated in the
BENEFIT and CHAGASAZOL studies.
BZN dosage and side effects
BZN usual dosage has been 5mg per kg of body weight
per day for 30 to 60 days [14]. This dosage is not free of
side effects, including dermatitis, which usually occurs
during the first weeks, and ocassionally peripheral neur-
opathy, which seems to be related to the cumulative
dose and may take months to resolve [14, 19, 20].
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Gastrointestinal effects, including vomiting and pain, are
also frequent side effects that can be theoretically pre-
vented by diet. Other severe adverse events, although in-
frequent, are bone marrow depression, toxic hepatitis,
and lymphomas [20]. In the BENEFIT trial, the initial
regimen of 5 mg per kg of body weight per day for 60
days was modified to a fixed dose of 300mg per day for
40 to 80 days [17]. Of concern, the rate of treatment
interruption because of an adverse event was 23.9% in
the BZN group compared to 9.5% in the placebo group.
Additionally, 13.4% of patients in the BZN group per-
manently discontinued treatment compared to 3.6% in
the control group. Dermatitis, digestive intolerance, and
neuropathy accounted for more than 90% of the inter-
ruptions [17]. Other studies suggest that the adverse
events rate tends to be lower in children and young
adults [13, 18, 20].
Minimizing side effects of BZN treatment is a priority,
as it may prevent harm and increase compliance [14].
This is especially important for prevention of congenital
transmission purposes in a population of infected but
mostly still healthy young women. In Argentina, the fear
of side effects limits the implementation of the guideline
recommending BZN 60d treatment of T. cruzi seroposi-
tive women during the postpartum period to prevent
transmission in a future pregnancy [14].
Do shorter BZN treatments reduce major side effects
and increase compliance, compared to the standard 60d
course? Thirty-day treatments have been used in non-
randomized intervention studies, suggesting they might
be as effective as a longer treatment and may prevent se-
vere effects like peripheral neuropathy and bone marrow
depression [21]. However, 30d courses may not prevent
the most frequent adverse events like dermatitis and di-
gestive intolerance.
Do lower dose BZN courses reduce major side effects,
compared to the standard 5 mg/kg/d or 300 mg/d? Der-
matologic effects seem to be idiosyncratic and not dose-
related [20]. Pinazo and colleagues found no correlation
between BZN levels and the incidence of adverse events
in a population of 54 adult patients who were T. cruzi
seropositive [22]. However, a pilot study evaluating a 5
mg/kg intermittent treatment for 60d showed that while
adverse events were reported by 50% of the subjects, the
severity of the effects was mostly mild and that treat-
ment interruption occurred in only one subject. The au-
thors concluded that reducing the dose by intermittent
courses might reduce adverse events and that experi-
mental studies are warranted [23]. Further evidence
comes from PK studies in children and adults. Children
show a lower incidence of adverse events than adults,
but the mechanisms responsible for the age difference
are still unclear; the enzymatic activity of nitro-
reduction and generation of free radicals, which is low in
children, as well as the higher clearance of BZN in chil-
dren, with lower accumulation compared to adults, are
among the postulated mechanisms [18, 20]. Altcheh and
colleagues conducted a PK study in children and a
model-based analysis, including adult data from previous
BZN studies [18]. They observed that BZN concentra-
tions in children were markedly lower than those re-
ported in adults (treated with comparable mg/kg doses).
Treatment was well tolerated with few adverse effects, a
marked difference from adults. The authors suggest that
it is conceivable that a BZN dose reduction for adults,
which would result in systemic exposures similar to
those in children, would not have a detrimental impact
on treatment response and could lead to a reduction in
the incidence of adverse events.
BZN dosage and trypanocidal effect
No randomized controlled trial has been published thus
far comparing the trypanocidal effect of courses shorter
than 60 days, or courses with low BZN doses. A BZN
30d course with 5 mg/kg daily is generally accepted as a
complete treatment in Argentina but is only supported
by non-experimental evidence of non-inferiority com-
pared to 60d [20].
There is indirect evidence supporting the potential ef-
ficacy of shorter courses from a cohort study in
Argentina, following up 81 patients that permanently
discontinued BZN treatment (5 mg/kg/d for 30 days) due
to side effects. The median duration of treatment was
10 days, with 75% of the patients discontinuing before or
at 15 days [24]. At follow-up at 9 years, 20% of these pa-
tients seroconverted in three T. cruzi serological tests
and 39% of the patients seroconverted in only one test.
One interesting study in mice has shown that shorter
courses, with as few as 13 doses of BZN at five-day in-
tervals, perform equally well in cure rates than 40 daily
doses. These results question the presumption that the
effectiveness of BZN depends on sustaining a concentra-
tion above the minimum inhibitory concentration, sug-
gesting that the effect may be produced through a
“maximum concentration mechanism” with extended
post-treatment effects and an impact on pathogen
growth after complete elimination of the drug [25]. The
authors also suggest that standard BZN protocols may
be significantly overdosing patients, perhaps contribut-
ing to the adverse events.
A recently published study in T. cruzi-infected mice
compared the effect of different BZN doses and the dur-
ation of treatment on parasitological cure in both acute
and chronic infection. A dose of 30 mg/kg (30% of the
standard dose in mice) during 10 and 20-day treatments
showed a 67 and 100% cure rate in chronic infections,
respectively [26]. In contrast, acute infections showed
substantially lower cure rates with either reduced doses
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or duration of treatment. These results support the pos-
sibility of reducing treatment duration and drug dose in
chronic infections, as suggested by the authors.
In another prospective population PK study, the au-
thors investigated 39 patients receiving 5 mg/kg daily
doses of BZN for 60 days, then built and compared sim-
ulated models of 5 mg/kg daily and 2.5 mg/kg daily [27].
Assuming an acceptable BZN plasma concentration
range of 3–6mg/l, the median concentration with the
standard dose was above 6 mg/l in all cases. With half
doses, all cases showed concentration always within the
3–6 mg/l range. These results support the views of other
authors, suggesting that standard treatment protocols
using BZN might be significantly overdosing patients
and that studies with lower doses in adults might be jus-
tified [18, 25].
Thus, in summary, there is currently no experimental
evidence in humans evaluating whether BZN treatments
that are shorter or lower dose than 5mg/kg daily for 60
days have a non-inferior trypanocidal effect with fewer
adverse events. Observational, animal, and PK studies
suggest that the standard scheme may be overdosing pa-
tients unnecessarily and increasing adverse events. RCTs
testing alternative BZN courses are therefore a priority.
Ongoing studies
To our knowledge, two RCTs that compare different
BZN treatment schemes combining different length and
dosage are ongoing. The BENDITA trial compares a
BZN course of 300 mg daily for 30 days with the stand-
ard course of 300 mg daily for 60 days in T. cruzi sero-
positive subjects with chronic indeterminate phase and
positive PCR (S. Sosa-Estani, personal communication).
The MULTIBNZ trial compares BZN 400mg daily for
15 days, BZN 150mg daily for 60 days, and BZN 300mg
daily for 60 days in 240 adults with and without organ
compromise and positive PCR [28].
Methods/ study design
The format of this section is adapted from the
“Methods” section of the CONSORT checklist for non-
inferiority randomized controlled trials [29].
Overview
We are proposing to perform a double-blinded, non-
inferiority randomized controlled trial comparing short
low dose 30d/150 mg BZN vs. 60d/300 mg BZN. We will
recruit not previously treated T. cruzi seropositive
women with a live birth during the postpartum period in
Argentina, randomize them at 6 months postpartum (to
avoid interfering with breastfeeding), and follow them
up (Fig. 1).
Screening for anti-T. cruzi antibodies during antenatal
care is standard of care in Argentina [14]. Two
serological tests, indirect haemagglutination antibody
assay (IHA) and enzyme-linked immunosorbent assay
(ELISA) are routinely performed, and mothers are classi-
fied as seropositive if they are positive for both. The in-
formation is registered on antenatal cards and/or clinical
histories. If case information is not available at delivery,
serological tests are routinely performed on cord blood.
We will identify seropositive mothers with at least one
positive or indeterminate test and obtain written in-
formed consent (Consent A) to interview them and to
collect maternal blood as soon as possible after delivery.
For mothers < 16, we will obtain written assent and writ-
ten consent from at least one parent or guardian (Assent
A and Parental Consent A). If the woman accepts to
participate, we will interview her and verify her eligibil-
ity. If the mother is eligible, we will collect maternal
blood. We will verify the T. cruzi seropositivity of
mothers with positive antenatal serology by performing
an additional IHA and ELISA (Wiener laboratories, Ros-
ario, Argentina). Mothers will be confirmed as seroposi-
tive if they are positive for both tests.
Mothers confirmed as seropositive will be visited at
home 4–8 weeks postpartum, will be invited to partici-
pate in the randomized controlled trial, and will be re-
quested to provide written informed consent (Consent
B) specific to trial participation. For mothers < 16, we
will obtain written assent and written consent from at
least one parent or guardian (Assent B and Parental
Consent B). Before treatment, we will perform examina-
tions recommended by the Argentine standards of care,
including: EKG, echocardiogram, and chest X-ray [14].
We will also perform complete blood count (CBC), kid-
ney function tests, and liver function tests before treat-
ment and at least once during treatment. Modern
contraceptive methods will be provided during treat-
ment. During treatment, we will monitor participants at
least once a week for adverse events and adherence and
collect DBS for measuring BZN blood levels during the
first 30 days of treatment. We will collect blood for T.
cruzi PCR immediately before treatment, at the end of




To measure the effect of BZN 30d/150 mg compared to
60d/300 mg preconceptional treatment on parasitic load
measured by the frequency of positive PCR (primary
outcome) and by real-time quantitative PCR (qPCR), im-
mediately (Specific Aim 1a) and 10months (Specific
Aim 1b) after treatment.
Hypothesis 1a: the frequency of positive PCR and the
parasitic load measured by qPCR immediately after BZN
30d/150 mg will be non-inferior (Non-Inferiority (NI)
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margin for PCR: 10% absolute difference) to BZN 60d/
300 mg.
Hypothesis 1b: the frequency of positive PCR and the
parasitic load measured by qPCR 10months after BZN
30d/150 mg will be non-inferior (NI margin for PCR: 9%
absolute difference) to BZN 60d/300mg.
Secondary hypotheses/secondary outcomes
To measure the frequency of serious adverse events and/
or any adverse event leading to treatment interruption
of BZN 30d/150mg compared to 60d/300 mg.
Hypothesis 2: the frequency of serious adverse events
and/or any adverse event leading to treatment
Fig. 1 Study design
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interruption will be 50% lower with BZN 30d/150 mg
than with BZN 60d/300 mg.
Study population and procedures
Study sites and population
Participating sites: include public health facilities in three
endemic provinces in Northern Argentina: Chaco,
Santiago del Estero, and Tucumán (Table 1). Women
giving birth in these settings have a median age of 23
years old (interquartile range 19–29) [30]. We are plan-
ning on enrolling women during a two-year period.
Inclusion and exclusion criteria
Inclusion criteria:
– Written informed consent if 16 or older; for
mothers < 16, we will require written assent and
written consent from at least one parent or
guardian.




– Women residing outside of the provinces of Chaco,
Santiago del Estero, or Tucumán.
– Previous trypanocide treatment (BZN or
Nifurtimox).
– Female sterilization; no intention to use modern
contraception methods during treatment.
– Positive pregnancy test.
– History of severe alcohol abuse within 2 years; renal
insufficiency.
Sampling, recruitment, and screening procedures
We will identify not previously treated T. cruzi seroposi-
tive women (with at least one positive or indeterminate
test) with a live birth during the postpartum period and
obtain written informed consent (Consent A) to inter-
view them and to collect maternal blood as soon as pos-
sible after delivery. For mothers < 16, we will obtain
written assent and written consent from at least one par-
ent or guardian (Assent A and Parental Consent A). If
the woman accepts to participate, we will verify her eligi-
bility. If she is eligible we will collect maternal blood and
will verify T. cruzi seropositivity by two tests: ELISA and
IHA. Mothers confirmed as seropositive will be visited
at home 4–8 weeks postpartum, will be invited to par-
ticipate in the randomized controlled trial, and will be
requested to provide written informed consent (Consent
B) specific to trial participation. For mothers < 16, we
will obtain written assent and written consent from at




Between the fourth to sixth months postpartum, we will
perform examinations recommended by the Argentine
standards of care, including EKG, echocardiogram, and
chest X-ray [14]. We will use the Kuschnir classification
(0-III) of Chagas disease severity [14, 31]. We will also
perform CBC, kidney function tests, liver function tests,
and pregnancy tests. These procedures will be done by
the Clinical Care Unit (CCU) specifically organized for
this study (see Clinical care during treatment).
Study medication
Procurement of study drugs, obtaining placebo,
development of interventions
We will use a preparation of BZN that is commercially
available in Argentina: Abarax® 50 mg tablets from ELEA
laboratories (Buenos Aires, Argentina). ELEA laborator-
ies will prepare the placebo tablets, which will be identi-
cal to the drug tablets in aspect and taste. We will
purchase the drug and placebo at full cost. Samples of
10 tablets of each lot of drug and placebo will be sent to
the University of California San Diego (UCSD) for qual-
ity control (see Laboratory analysis).
Randomization procedures
The biostatistician (Dr Shaffer) from the Tulane School
of Public Health and Tropical Medicine will generate a
random allocation sequence using computer-generated
random numbers in balanced blocks of variable sizes,
stratified by site. ELEA laboratories (Argentina) will pre-
pare the treatment and placebo tablets. Kits with the
Table 1 Participating health facilities: eligible women in 2015






Hospital J.C. Perrando (Chaco) 5820 186 3.2
Hospital Regional Dr. Ramón Carrillo (Santiago del Estero) 6204 180 2.9
Centro Integral de Salud La Banda (Santiago del Estero) 2720 131 4.8
Instituto de Maternidad y Ginecología Nuestra Señora de las Mercedes (Tucumán) 8692 130 1.5
Total 23,436 627
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two treatment regimens: the 60d standard treatment and
the 30d treatment completed with a 30d placebo will be
prepared by a packaging company in Argentina. Kits will
be identical and will be assigned a lot number, expir-
ation date, and a tracking number (alpha-numeric, with
check digit). Treatment allocation will be carried out
using an internet-based randomization service
(randomize.net) [32]. Each health facility trial unit will
have a computer connected to internet provided by the
study. Participant eligibility criteria will be entered and
confirmed in REDCap and then the participant data will
be entered in randomize.net, which will assign a
uniquely numbered kit. The system maintains the cap-
acity for managing the stock of kits, assigning replace-
ment kits, or reporting emergency unblinding, if needed.
Informed consent/assent
All T. cruzi seropositive women who are delivering a live
newborn at the four participating health facilities will be
sought for inclusion as potential study subjects. Women
who decline to sign a consent/assent form, pregnant
women, women who previously received trypanocidal
treatment, women with history of severe alcohol abuse,
women with renal insufficiency and women residing out-
side of the follow-up areas will be excluded.
Participating sites include: Hospital J.C. Perrando
(Chaco), Hospital Regional Dr. Ramón Carrillo (Santiago
del Estero), Centro Integral de Salud La Banda (Santiago
del Estero) and Instituto de Maternidad y Ginecología
Nuestra Señora de las Mercedes (Tucumán). The protec-
tion of human subjects has been adequately addressed
among the collaborating institutions at a level that is at
least as high as that documented at the applicant
organization, the Tulane University School of Public
Health and Tropical Medicine (SPHTM).
Participation in this research is absolutely voluntary.
This study will be conducted following strict guidelines
for the protection of the rights of human volunteers. We
will identify seropositive mothers and obtain written in-
formed consent (Consent A) to interview them and to
collect maternal blood as soon as possible after delivery.
For mothers < 16, we will obtain written assent and writ-
ten consent from at least one parent or guardian (Assent
A and Parental Consent A). If the woman accepts to
participate, we will interview her and verify her eligibil-
ity. If the mother is eligible, we will collect maternal
blood. We will verify the T. cruzi seropositivity of
mothers with positive antenatal serology by performing
an additional IHA and ELISA (Wiener laboratories, Ros-
ario, Argentina). Mothers will be confirmed as seroposi-
tive if they are positive for both tests.
Mothers confirmed as seropositive will be visited at
home 4–8 weeks postpartum, will be invited to partici-
pate in the randomized controlled trial, and will be
requested to provide written informed consent (Consent
B) specific to trial participation. For mothers < 16, we
will obtain written assent and written consent from at
least one parent or guardian (Assent B and Parental
Consent B).
Informed consent/assent forms must be signed by all
participants. The consent/assent forms will clearly state
the study purpose, eligibility criteria and protocol of the
study, the potential benefits and risks of participation,
and participants’ rights to refuse to participate or with-
draw from the study. Additionally, the consent and
assent forms and any other materials will be available in
both Spanish and English.
If a woman declines to participate, no data will be
collected.
Confidentiality
Data will be collected on paper forms or tablets, and a
study identification numbering system (alpha-numeric,
with check digit) will be designed specifically for this
study. Freezer-safe barcode or QR code labels (Brady,
Milwaukee, WI) will be pasted on each of the biological
samples for identification. An inclusion form will be
used to collect data during participants’ enrollment.
Names and other personal identifiers will be recorded in
the inclusion form header, which will be redacted from
the main body containing data. Each participant will be
identified with a study label number. The inclusion form
body will be entered into REDCap at each site; names
and other personal identifiers will not be entered. This
system will ensure that personal identifiers are restricted
to the study site and granted only via secure access
through the site coordinator.
Management and retention of study populations
Clinical care during treatment
At each participating health facility, we will set up a
CCU with at least one clinician in charge, including a
cardiologist, who will conduct the clinical assessments
and will provide their clearance for the women to be
randomized. The participating health facilities have the
necessary equipment to perform these procedures, and
the study will provide all necessary supplies. All tests
and diagnostic procedures results will be securely stored
at the CCU. The CCUs will also provide clinical care
during treatment to the participating women. This study
organization has been successfully used in cardiovascular
risk factors cohort studies enrolling 8000 adults in
Argentina, Chile, and Uruguay and conducted by the
Instituto de Efectividad Clínica y Sanitaria (IECS) [33].
Treatment will be prescribed and monitored at each
health facility CCU following the Argentine standards
[14]. Before the start of the treatment, we will provide
participants with their chosen contraceptive methods.
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During treatment, we will monitor participants at least
once a week by phone or SMS, and at biweekly health
facility or home visits, for adverse events and adherence.
CBC, kidney function tests, and liver function tests will
be performed at least once during treatment.
Follow-up
Women will be followed up until the end of the study
follow-up period, 10 months after treatment. To this
purpose, a dedicated team in each province will coordin-
ate the follow-up. To maintain updated contact details,
participants will be contacted every 2 months by SMS or
phone calls. Participants will receive a home visit or a
health facility appointment at 10 months after treatment.
Reimbursements
Enrolled women will not receive any payment for par-




We will use a preparation of BZN that is commercially
available in Argentina: Abarax® 50 mg tablets from ELEA
laboratories (Buenos Aires, Argentina). ELEA laborator-
ies will prepare the placebo tablets, which will be identi-
cal to the drug tablets in aspect and taste. We will
purchase the drug and placebo at full cost. Samples of
10 tablets of each lot of drug and placebo will be sent to
UCSD for quality control (see Laboratory analysis).
Intervention group: BZN short course low dose
scheme will be 150mg per day for 30 days. The treat-
ment will start with the active drug and then placebo;
two 50mg tablets and one placebo tablet in the morning
and one 50 mg tablet and two placebo tablets in the
evening for the first 30 days. The last 30 days will be
three placebo tablets in the morning and in the evening.
Control group: BZN standard course will be 300mg
per day for 60 days, which is similar to the dose used in
the second phase of the BENEFIT trial [17]. The drug
will be administered orally in two doses per day: three
50mg tablets in the morning and in the evening for 60
days.
This order will allow both trial arms to start with the
active drug and prevent the risk of unblinding that may
happen at the occurrence of adverse events in the first
30 days.
Protocol deviations
A specific report will be produced to account for poten-
tial protocol deviations after each phase of the study.
The sponsor, the Tulane Institutional Review Boards
(IRB), and the local IRBs will be notified of any protocol
deviations.
Adherence monitoring
To monitor adherence, we will use self-report, with a
single item visual analogue rating scale performed at the
visits to the CCU [34]. Additionally, we will collect DBS
for measuring BZN blood levels during the first 30 days
of treatment.
Adverse events
The risks associated with this protocol involve the ad-
verse events (AE) caused by the BZN that were included
as secondary outcomes: dermatitis, which usually occurs
during the first weeks, peripheral neuropathy, which
seems to be related to the cumulative dose and may take
months to resolve, and gastrointestinal effects, including
vomiting and pain; other severe adverse events, although
infrequent, are bone marrow depression, toxic hepatitis,
and lymphomas. These adverse events are considered in
the secondary outcomes of this study.
Other immediate risks associated with this protocol in-
volve the drawing of venous blood. Occasionally, sub-
jects can feel faint or light-headed, but this is rare and
passes by having the subject lie down for a few minutes.
Infection is a potential risk, but this risk will be mini-
mized as all specimens will be obtained aseptically by
trained personnel.
Reporting procedures
AEs and serious adverse events (SAEs) will be reported
and compiled at each site. They will be forwarded to the
Study Data Center (SDC) and to the Principal Investiga-
tors (PIs), Pierre Buekens, MD, PhD, in New Orleans,
Louisiana, USA, and Maria Luisa Cafferata, MD, in Bue-
nos Aires, Argentina. The sponsor and local IRBs will be
notified of any adverse events (when is applicable). Ad-
verse events will be documented in the annual report.
Measurement methods - variables
Description of biological clinical and socio-demographic
measures and sources
Maternal characteristics at enrollment
– A confirmed seropositive mother will have at least
two positive tests on maternal blood [35];
– Date of delivery (day/month/year) of a live birth (a
baby born with any sign of life, irrespective of
gestational age);
– Date of birth (day/month/year); maternal age
(years);
– Educational level (completed years);
– Parity (including current birth); reproductive history
(year of occurrence): previous pregnancies,
abortions, stillbirths, live births, infant’s or children’s
death; last menstrual period (LMP) (day/month/
year);
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– Smoking status (yes/no); severe alcohol abuse (yes/
no): 4 or more drinks on any day or 8 or more
drinks per week [36] maternal weight (kg); maternal
height (cm); Body Mass Index (BMI) (kg/m2);
– Human Immunodeficiency Virus (HIV) serology
(according to tests performed routinely in each
health facility) (positive/negative);
– Screening for T. cruzi (day/month/year); previous
trypanocide treatment (BZN or Nifurtimox) (yes/
no);
– Household location and municipality; household
latitude and longitude (decimal degrees).
Women’s characteristics before and during preconceptional
treatment
– Contraception method: implant, copper intrauterine
device, hormonal intrauterine system, injectable,
hormonal contraceptive pill, barrier methods;
– Renal insufficiency (serum creatinine > 2.5 mg/dL or
200 μmol), hepatic insufficiency (AST/ALT >3x
normal) [17], EKG, echocardiogram, and chest X-
ray (BENEFIT trial criteria [17] and Kuschnir classi-
fication (0-III) of Chagas disease severity [14, 31];
– Adherence to treatment: single item visual analogue
rating scale (0–100%) [34] and BZN DBS
concentration (μg/mL); other medications (name,
dosage);
– Adverse events: dermatitis (yes/no), gastrointestinal
(yes/no), severe leukopenia (< 2500 white blood
cells/μL), peripheral neuropathy (yes/no), others
(description).
Data sources
Clinical data, socio-demographic data, and geographical
data
Clinical data and socio-demographic data
Data will be collected from the medical histories and by
interviewing the mothers. Study personnel will be
trained in abstracting medical histories. Participating
health facilities use the format of the Perinatal Informa-
tion System of Pan American Health Organization
(PAHO)/World Health Organization (WHO) [37]. Data
on CBC, kidney function tests, liver function tests, EKG,
echocardiogram, and chest X-ray will be collected by the
CCUs.
Geographical data
Street addresses will often be unreliable in the areas
where participating women live; thus, detailed informa-
tion will be collected at enrollment:
– Household location (addresses will be registered if
available);
– Municipality of residence. Interviewers will have a
list of municipalities available during the interview
and verify that the name of the municipality is valid;
– Phone numbers of the participants.
During the first home visit, considerable effort will be
made to locate the household, involving key informants,
if needed. Once located, we will use GPS to map the lo-
cation of the household. The latitude and longitude of
the main entrance will be determined after obtaining the
appropriate GPS signal, and additional characteristics of
the household will be noted. To facilitate future house-
hold visits, the GPS coordinates will be entered into a
GIS database (ArcView Geographic Information Systems
[ArcGIS] for Desktop Version 10.3 or higher, Environ-
mental Systems Research Institute, Redlands, CA).
Schedule of data collection
Screening
Before delivery, we will identify seropositive mothers
with at least one positive or indeterminate test and ob-
tain written informed consent (Consent A) to interview
them and to collect maternal blood as soon as possible
after delivery. For mothers < 16, we will obtain written
assent and written consent from at least one parent or
guardian (Assent A and Parental Consent A). If the
woman accepts to participate, we will interview her and
verify her eligibility. If the mother is eligible, we will col-
lect maternal blood. We will verify the T. cruzi seroposi-
tivity of mothers with positive antenatal serology by
performing an additional IHA and ELISA (Wiener la-
boratories, Rosario, Argentina). Mothers will be con-
firmed as seropositive if they are positive for both tests.
If the mother has a live birth, is T. cruzi positive con-
firmed by at least two positive tests, did not receive pre-
vious T. cruzi treatment, and lives within the study’s
follow-up area, then she will be eligible for enrollment in
the study.
Enrollment and follow-up
Mothers confirmed as seropositive will be visited at
home 4–8 weeks postpartum, will be invited to partici-
pate in the randomized controlled trial, and will be re-
quested to provide written informed consent (Consent
B) specific to trial participation. For mothers < 16, we
will obtain written assent and written consent from at
least one parent or guardian (Assent B and Parental
Consent B).
Before treatment, we will perform examinations rec-
ommended by the Argentine standards of care, including
EKG, echocardiogram, and chest X-ray [14]. We will also
perform CBC, kidney function tests, and liver function
tests before treatment and at least once during treat-
ment. Pregnancy tests will be performed before and
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during treatment. Modern contraceptive methods will be
provided during treatment. During treatment, we will
monitor participants at least once a week for adverse
events and compliance with the study medication. We
will plan a visit every 2 weeks at the health facility or at
home. During the first 30 days of treatment, we will
monitor adherence and will collect DBS for measuring
BZN blood levels. We will collect blood for T. cruzi PCR
immediately before treatment, at the end of the treat-
ment (30 and 60 days), and 10 months after treatment
(Table 2).
Early termination visit
Subjects may withdraw voluntarily from participation in
the study at any time. However, we estimate that the loss
to follow-up will be lower than 5%. In the event of early
termination, we will attempt to conduct the follow-up
visit procedures early, if the participant is willing.
Questionnaire administration
Data will be collected on paper forms or tablets, and a
study identification numbering system (alpha-numeric,
with check digit) will be designed specifically for this
study. Freezer-safe barcode or QR code labels (Brady,
Milwaukee, WI) will be pasted on each of the biological
samples for identification. An inclusion form will be
used to collect data during participants’ enrollment.
Names and other personal identifiers will be recorded in
the inclusion form header, which will be redacted from
the main body containing data. Each participant will be
identified with a study label number. The inclusion form
body will be entered into REDCap at each site [38];
names and other personal identifiers will not be entered.
This system will ensure that personal identifiers are re-
stricted to the study site and granted only via secure ac-
cess through the site coordinator.
Collection of biological samples/shipping
Blood samples
We will collect blood for T. cruzi PCR immediately be-
fore randomization as a baseline measurement. For Spe-
cific Aim 1, we will collect blood after the end of the
treatment with the active drug in each arm (as treat-
ments are masked, we will collect blood in both arms at
30 and 60 days after randomization), and at 10 months
after treatment. For Specific Aim 2, we will collect blood
for CBC, kidney function tests, and liver function tests
before treatment and at least once during treatment. In
addition, we will collect information on parasitological
and serological examinations routinely performed
among infants born alive to a T. cruzi seropositive
mother according to national policies, including direct
parasitological examination on cord blood [14].
We estimate from our previous studies that less than
1% of the samples will be unusable.
Serology: 5 ml of maternal venous blood will be col-
lected in EDTA tubes for plasma.
PCR: 5 ml of maternal venous blood will be collected
in tubes with 5 ml guanidine-HCl 6M, EDTA 0.2M
(pH 8).
BZN measurement: DBS will be collected on What-
man 903 Sample Collection Cards (GE Healthcare Bio-
Sciences, Pittsburgh, PA) or equivalent.
Storage of biological samples
Consent/assent forms will include the authorization to
participating study institutions to store blood specimens
for up to 10 years for confirmatory studies related to the
primary outcomes, and an opt-out option allowing the
use of stored specimens for other confirmatory studies
(including diagnosis of co-infections) and for potential
human genetic studies linked to mother-to-child trans-
mission of T. cruzi. This is similar to our previous study,
in which less than 1% of the participating women did
not accept the storage.
Table 2 Summary of procedures




Maternal venous blood 5ml EDTA
for plasma
ELISA and IHA Filter paper 4 °C
Plasma/serum − 20 °C
4–8 weeks postpartum Home visit to provide consent to be randomized (Consent/Assent B)
Before randomization Clinical assessment
6 months postpartum Randomization to BZN 30d/150mg (intervention arm) or BZN 60d/300mg (control arm)
Before treatment Maternal venous blood 5ml PCR 10 ml blood-Guanidine 4 °C
Once a week Monitoring adverse events
During treatment Maternal finger prick/
venous blood
DBS BZN concentration Filter paper −20 °C
End of treatment Maternal venous blood 5ml PCR 10 ml blood-Guanidine 4 °C
10 months after treatment Maternal venous blood 5ml PCR 10 ml blood-Guanidine 4 °C
Cafferata et al. Reproductive Health          (2020) 17:128 Page 11 of 23
Blood samples will be stored in part on filter paper
kept in plastic bags with a desiccant at 4 °C until use,
and additional plasma and/or serum samples will be fro-
zen at or below − 20 °C until use. Freezing-defreezing cy-
cles of plasma and/or serum aliquots will be kept to a
minimum. The blood samples to be stored for PCR will
be collected in tubes with guanidine-HCl 6M, EDTA
0.2M (pH 8) and kept at 4 °C until processed.
Aliquots of each blood sample will be stored in-
country. In addition, aliquots of frozen plasma and/or
serum will be shipped on dry ice to Tulane University
and stored at the SPHTM freezer farm, located in a safe
area at the Tulane National Primate Research Center,
35 miles north of New Orleans. Aliquots of blood on
guanidine will also be stored in-country and at the
Tulane SPHTM.
Freezer-safe barcode or QR code labels (Brady, Mil-
waukee, WI) will be pasted on each of the biological
samples and will be scanned to document the location
of the samples. Temperatures of freezers, refrigerators,
and the storage place for study medication will be moni-
tored by digital temperature data loggers (SM320, Dick-
son, Addison, IL, or equivalent). The SDC will manage
the barcode and temperature data (see Data collection
and management).
Shipping
Each site will ship tubes containing blood/guanidine/
EDTA mixtures (10 mL), and labeled tubes containing
plasma and/or serum, to the Laboratorio de Biología
Molecular de la Enfermedad de Chagas (INGEBI) in
Buenos Aires by World Courier or similar door to door
service. Such sending and shipping to INGEBI should
not raise problems, according to World Courier. INGEBI
will ship the tubes to the SPHTM in New Orleans, Lou-
isiana, USA.
Each site will ship DBS filter papers to INGEBI in Bue-
nos Aires, and INGEBI will ship the samples to the
USD, California, USA.
For quality assessment, INGEBI will ship tubes con-
taining blood/guanidine/EDTA mixtures (10 mL) to the
Instituto Nacional de Parasitología (INP) or a similar ref-
erence laboratory in Buenos Aires for qPCR and PCR.
Labeled tubes containing blood/guanidine/EDTA mix-
tures (10 ml/tube) will be stored at 4 °C until shipped to
Buenos Aires and New Orleans, but the shipping can be
done at ambient temperature.
Labeled tubes containing plasma and/or serum will be
stored at or below − 20 °C until shipped to Buenos Aires
and New Orleans, and the shipping will be done on dry
ice or similar. DBS filter papers will be stored at or
below − 20 °C until shipped to Buenos Aires and San
Diego, California.
Biosecurity safety procedures
All blood sample extraction procedures will comply with
biosecurity safety procedures. All laboratory personnel
will be trained in handling biohazardous materials. This
training will be conducted before the study begins.
“Sharps” boxes for appropriate storage of needles and
other sharps will be located in the laboratory and appro-
priately discarded. Biohazardous materials will be dis-
carded in appropriately labeled receptacles. They will be
autoclaved and then discarded in appropriate biohazard-
ous waste facilities.
Laboratory analysis
Investigators and staff performing the laboratory proce-
dures will be blinded for the BZN treatment schemes
status and for other characteristics of the participants.
Conventional PCR and qPCR will be performed inde-
pendently using the same methodologies in two different
laboratories: INGEBI and the SPHTM. External quality
assessment will also be conducted at the SPHTM for
serology and at the INP or a similar reference laboratory
for conventional PCR and qPCR.
Serology
Samples will be analyzed at each of the four enrolling
health facilities with two commercial tests (Wiener la-
boratories, Rosario, Argentina): an ELISA prepared with
recombinant T. cruzi antigens (Chagatest ELISA recom-
binant, version 3.0 or higher) and an IHA test, according
to the manufacturer’s protocols.
DNA extraction and conventional PCR
We will use the following procedures, or equivalent
ones. DNA will be extracted using Qiagen DNA extrac-
tion kits (or equivalent). The concentration and quality
of DNA will be measured at 260/280 nm. The presence
of T. cruzi DNA in purified DNA extract will be tested
by two conventional PCRs using primers amplifying nu-
clear microsatellite DNA repeats (SatDNA) (Tcz1/Tcz2,
giving amplicons of 182 pb) and kinetoplastic DNA re-
peats from minicircle domains (kDNA) (Tc121/Tc122,
giving amplicons of 320 pb). Each sample will be also
analyzed for the human β-globin fragment to verify the
integrity of the DNA extracted and the lack of PCR in-
hibitors. PCR products will be separated on 2% agarose
gels and visualized with ethidium bromide or SYBR® Safe
DNA Gel Stain. Those samples demonstrating the spe-
cific bands for one or both molecular targets will be con-
sidered T. cruzi-positive. All samples will be analyzed in
duplicate. The detection limit of such PCRs was esti-
mated to 0.1 to 1 parasite equivalent/mL [39]. Molecular
characterization of T. cruzi Discrete Typing Units
(DTUs) will be carried out using a barcoding approach
based on the mini-exon marker, which has been
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previously standardized, and the PCR conditions im-
proved by our group. We will first amplify the intergenic
region of T. cruzi mini-exon using an improved multi-
plex PCR with the primers reported by Souto et al. [40]
which allows for identification of TcI and non-TcI
DTUs. Also, we have improved the PCR sensitivity de-
tection using a simple PCR with primers TrypME3 and
TccH, designed by our group, that produce a larger frag-
ment of 500 bp. All amplicons will be processed for
next-generation sequencing, and sequences will be ana-
lyzed using Geneious 11 to identify parasite DTUs
present in samples.
Real-time quantitative PCR (qPCR)
We will use the following procedures, or equivalent
ones. A validated duplex qPCR method based on Taq-
Man probes, targeting T. cruzi SatDNA (primers cruzi1/
cruzi2 and TaqMan probe cruzi3), will be performed
with 5 μL of eluted DNA using FastStart Universal Probe
Master Mix (Roche Diagnostics GmbHCorp., Mann-
heim, Germany) in a final volume of 20 μL [41, 42]. Two
slight modifications in PCR reagents will be introduced
to published procedures: Uracil-DNA Glycosylase (UDG,
Thermo Fisher Scientific, Rockford, IL) incorporation to
the reaction mix, as a carry-over contamination control,
and the use of human RNAse P gene as the internal
amplification control using TaqMan RNase P Control
Reagents Kit (Applied Biosystems, Foster City, CA) at a
final concentration of 0.5X. The amplification will be
performed in a CFX96 Touch Real-Time PCR Detection
System (BioRad) device or similar and cycling conditions
will be as follows: a first step of 2 min at 50 °C and a sec-
ond step of 10 min at 95 °C, followed by 40 cycles at
95 °C for 15 s and 58 °C for 1 min. All samples will be
analyzed in duplicate. The qPCR results will be con-
verted to an estimated parasitic load (parasite equiva-
lents/mL) using an appropriate standard calibration
curve.
External quality assessment
External quality assessment will be performed at the
SPHTM for serology and at the INP (Buenos Aires,
Argentina) or a similar reference laboratory for conven-
tional PCR and qPCR.
Proficiency testing: proficiency testing is defined as a
reference laboratory sending unknown samples for test-
ing to a set of laboratories. Five blinded panels, contain-
ing seronegative human blood samples spiked with 1, 10,
and 100 p/mL of cultured epimastigotes from CL-Brener
(TcVI) T. cruzi stock and negative controls will be pre-
pared at the INP, INGEBI, or a similar reference labora-
tory. Blood samples will be immediately mixed with one
volume of guanidine-HCl 6M, EDTA 0.2M (pH 8), and,
after 48 h at room temperature, stored at 4 °C until DNA
extraction and PCR/qPCR analysis. Each quality control
panel will be at three-month intervals, covering a period
of 1 year at the participating laboratories and the refer-
ence laboratory.
Retesting: retesting refers to samples that have been
analyzed being retested by a reference laboratory, allow-
ing for inter-laboratory comparison. Ten percent of sam-
ples from INGEBI will be sent to the reference
laboratories (SPHTM for serology and INP or a similar
reference laboratory for PCR) to be reanalyzed, using the
same standard operating procedures (SOP).
Measurement of BZN on DBS
BZN will be assayed by electrospray ionization mass
spectrometry after separation with HPLC. BZN will be
detected through monitoring the m/z = 261.3 (M+) tran-
sitions to product (daughter) ions 255.6, with collision
energies of 125 V.
Measurement of BZN in study medication
Measurement of BZN in study medication will be per-
formed at the beginning and/or at the end of the study
by electrospray ionization mass spectrometry after separ-
ation with HPLC. BZN will be detected through moni-
toring the m/z = 261.3 (M+) transitions to product
(daughter) ions 255.6, with collision energies of 125 V.
Acceptance criteria will be adapted from the U.S.
Pharmacopeial Convention using the content uniformity
(CU) method [43].
Primary and secondary outcome measures
Primary outcome: parasitic load measured by the fre-
quency of positive PCR (primary outcome) and by real-
time quantitative PCR (qPCR), immediately and 10
months after treatment.
Secondary outcome: frequency of serious adverse
events and/or any adverse event leading to treatment




Training will be performed for all study personnel and
will include: training in laboratory procedures, data col-
lection and data management, and ethical issues.
Training of Interviewers, Biological Sample Collectors,
and Laboratory Personnel will be done during the pre-
paratory phase, among other activities. This phase will
last approximately 12 months. The specific training ac-
tivities and training materials will be detailed in the
Manual of Operations. All personnel involved in the
study will be required to obtain certification ensuring
that they have met the training objectives. The SDC at
IECS will be responsible for developing this certification.
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The PI and Project Manager will be responsible for over-
seeing the certification process.
Detailed SOPs will be created describing all study
procedures.
Training in biosafety procedures for blood extraction
Health facility laboratory personnel include laboratory
technicians working at the health facility laboratories.
All laboratory personnel will be trained in how to handle
biohazardous materials. This training will be conducted
before the study begins. “Sharps” boxes for appropriate
storage of needles and other sharps will be located in the
laboratory and appropriately discarded. Biohazardous
materials will be discarded in labeled receptacles. They
will be autoclaved and then discarded in biohazardous
waste facilities.
Training in data collection
Field staff includes Field Research Coordinators, Follow-
up Coordinators, and Clinicians. Detailed SOPs have
been drafted to address all procedures to be carried out
by the study staff, including consent/assent, reporting of
AEs and SAEs to study physicians, and collection of
samples and case report form (CRF) completion at deliv-
ery, postpartum, and home visits. For specific aspects of
data collection, staff will be trained by senior study staff
with respect to assessment of the clinical status of the
women, collection of blood samples, and completion of
relevant CRFs.
Training in data management and entry
A detailed SOP will be developed for data entry and data
management. The Country Data Manager will be trained
in the conduct of accuracy and completion checks of
CRFs. He/she will also be trained in methods to query
the relevant individual completing the source documents
and CRFs with respect to missing data, illegible data, or
data that seems erroneous. Finally, the data manager will
be trained with respect to handling “out of range”
prompts encountered by data entry personnel.
Data entry staff will be trained in methods of data
entry of the CRFs into the REDCap system. The data
manager and data entry staff will receive relevant human
subjects training in confidentiality of data and handling
and storage of both the study source documents and
study CRFs.
Training in ethical issues
Before beginning any research activities, all study
personnel must participate in training on the proper im-
plementation of study procedures and the ethics of con-
ducting research with human subjects specifically
addressing administration of informed consent/assent,
confidentiality, and participants’ rights, including the
right to withdraw from the study at any time, the right
to register complaints about the study, etc. The PI will
ensure that all study personnel receive the appropriate
training. All personnel involved in the study will be re-
quired to obtain certification ensuring that they have
met the training objectives. The SDC at IECS will be re-
sponsible for developing a certification test. The PI and
Project Manager will be responsible for overseeing the
certification process.
Data collection and management
Overview
Data capture and management will be similar to the plan
we have used in previously-funded studies and will be
coordinated by IECS (Buenos Aires, Argentina). The
randomization sequence and interim data analyses will
be independently performed by the Tulane SPHTM bio-
statistician (Dr Shaffer). Data will be collected on paper
forms or tablets, and a study identification numbering
system (alpha-numeric, with check digit) will be de-
signed specifically for this study. A freezer-safe barcode
or QR code label (Brady, Milwaukee, WI) will be pasted
on each of the biological samples. An inclusion form will
be used to collect data during participants’ enrollment.
Names and other personal identifiers will be recorded in
the inclusion form header, which will be redacted from
the main body containing data. Each part will be identi-
fied with a study label number. The inclusion form body
will be entered into REDCap at each site [38]. This sys-
tem will ensure that personal identifiers are restricted to
the study site and granted only via secure access through
the site coordinator.
Data capture
The data forms will be entered in REDCap [38] which is
a cloud-based, open source application for capturing and
maintaining clinical research data. Paper forms of par-
ticipant who has signed informed consent will be
scanned or photographed and regularly uploaded to a
secure cloud server. Names and other personal identi-
fiers will not be included. This system will allow for a
digital backup of all study data forms. The SDC will
manage and link the information from the temperature
data loggers in the study freezers, refrigerators, and the
storage place for study medication and will utilize graphs
and alerts for detecting values out of the expected range.
The SDC will also manage the stock information from
the scanned biological samples barcodes.
Reports
For this trial, periodic reports will be prepared for review
by a Data Safety and Monitoring Board (DSMB). The
DSMB will be composed of an external peer review
group that will monitor the study enrollment and results
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from the study to ensure the safety and ethical treatment
of participants (see DSMB section below for composition
and duties). Additionally, weekly on-site visits to the par-
ticipating health facilities will be carried out by a desig-
nated Data Manager, who will complete weekly reports
and submit them to SDC staff. These staff will hold
weekly monitoring calls with each site Data Manager to
discuss site reports and will produce weekly summary
reports, which will be submitted to the PI and the co-
ordination unit. The PI and SDC staff will perform at
least one site visit per year. During these visits, source
data and biological samples verification will be per-
formed in 10% of all participants.
After each data collection period, the SDC will pro-
duce a summary report including the number of patients
who were included in the study period, missing data
rates, and inconsistent data rates. These reports will
present overall figures for the entire study and will also
be stratified by clinic.
An annual summary report will be produced and sent
to the Steering Committee. This report will include a
summary of the annual figures regarding data quality,
protocol violations, and adverse events.
Study data center
IECS will serve as the Study Data Center, providing a
specific data monitoring system, assuring maintenance
of high-quality databases, supervising all data collection
procedures, and arranging for the most efficient transfer
of study data. In addition, the Tulane SPHTM will pro-
vide statistical support and perform interim analyses and
reports for review by the DSMB.
The SDC at IECS will be responsible for planning, pre-
paring, and monitoring all data collection procedures
and will comply with good clinical practices (GCPs) to
ensure high quality data. SDC activities will include: pre-
paring data SOPs, training local Data Center staff for
data collection procedures, and monitoring sites’ data
collection procedures and quality, and ensuring the con-
fidentiality and safety of the data.
Adverse events
The SDC will incorporate AE and SAE reporting as an
essential component of data collection systems and
study monitoring. The SDC will prepare SAE reports for
reporting to IRBs and the funding source and will imple-
ment and maintain an email notification system to
promptly alert investigators of SAEs.
Statistical analysis
Data analysis plan and statistical methods
Data will be presented as means and standard deviations
and frequencies and percentages, as appropriate. A fixed
margin analytical approach will be applied [44], and
measures of effect will be quantified using risk differ-
ences (RD) with 95% confidence intervals (CI). The null
hypothesis of non-inferiority will be rejected if the upper
bound of the 95% CI for the RD comparison groups lies
below the fixed margin.
Analysis of primary and secondary hypotheses
For Specific Aim 1a, PCR measurements at completion
of treatment will be compared with the active drug in
each trial arm (30 and 60 days). More specifically, the
blood samples taken at 30 days will be used for the 30d
course arm, and the sample taken at 60 days will be used
for the 60d course arm. Because it has been shown that
PCR negative results may revert to positive after treat-
ment [17], this approach was chosen to ensure that the
outcomes are not measured at the same time in both
trial arms. A more conservative sensitivity analysis will
also be carried out using PCR measurement after 60 days
for both groups. For the 30d course arm, subjects whose
PCR status changes between the 30d and the 60d mea-
surements will be chronicled and reported. For Specific
Aim 1b, the comparisons will use the PCR measurement
taken at 10 months from the end of the 60-day treat-
ment period. In the event that the aforementioned sensi-
tivity analysis supports a secular trend bias, correcting
for any observed bias will be performed in the 10-month
analysis accordingly.
The analysis will be carried out separately based on
intention-to-treat (considering subjects lost to follow-up
as treatment failures) and per-protocol (excluding sub-
jects lost to follow-up or non-compliant) approaches.
Per-protocol analyses are recommended in non-
inferiority trials as a secondary approach [45]. Since it is
expected that part of the effect of the short treatment
arm could be mediated by an increase in compliance, a
per-protocol analysis controlling for compliance could
contribute to disentangle the mechanism of action. For
Specific Aim 2, all analyses will only apply intention-to-
treat approaches. Patterns of missing data will be exam-
ined separately for each trial arm. It is estimated that ap-
proximately 10% of PCR results will be missing at 10
months follow-up. Although unlikely, if more than 20%
of PCR results in either arm is missing, sensitivity ana-
lysis will be conducted on the effect of the missing data
on the inference using multiple imputation procedures
[46].
If PCR results at baseline show a clinically significant
imbalance between groups, generalized linear models
will be used to model RDs for the PCR results (primary
outcome), including the treatment as the primary pre-
dictor. An analysis of covariance (ANCOVA) approach
will be used to model qPCR results (secondary out-
comes), including baseline parasite equivalents/mL and
treatment as predictors. Treatment effects will be
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summarized by arithmetic and adjusted mean differences
in parasite equivalents/mL between the intervention and
control groups, with their corresponding 95% CIs. The
qPCR results will be considered on a log scale, as their
distribution was found to be right skewed in a previous
study. To explore whether the treatment affects qPCR
over the entire distribution of parasitic load values or
primarily through a reduction of high parasitic load
values, the skewness of the parasite equivalents/mL dis-
tributions will be tested and compared between the
treatment groups. Randomization tests will be used to
compare the absolute differences in skewness between
the two distributions [47]. If significant differences be-
tween the distributions are found, qPCR values will be
categorized and analyzed based on these categorical
values. All data analyses will be carried out using SAS
(Cary, NC) v9.3 or higher.
Sample size
For Specific Aim 1 and following Food Drug Adminis-
tration (FDA) and CONSORT guidance, we estimated
that the NI margin should preserve 75% of the effect of
60d/300 mg (considered as 100%) over placebo (consid-
ered as 0%) found in previous trials [29, 44]. The pri-
mary outcome is the frequency of positive T. cruzi PCR.
We estimated an effect on PCR conversion to negative
with BZN 60d of 80 and 30% with placebo. This is sup-
ported by: 1) the observed effects of BZN and placebo in
the BENEFIT study in Argentina and Bolivia, which
showed conversion rates from a positive to a negative
PCR of 73.0% in the BZN 60d group and 28.6% in the
placebo group at the end of treatment [17] and 2) the
therapeutic response to BZN treatment is better in
young and healthy subjects than in older subjects with
cardiomyopathy (see 1.2.2 Drug of choice for preconcep-
tional treatment). We will enroll mostly healthy young
women (median 23 years old), compared to the older
subjects (mean 55 years old) with cardiomyopathy par-
ticipating in the BENEFIT study. We used the 78.4%
positive PCR rate at delivery we found in our previous
study in Tucumán, Argentina [48].
Based on these figures, we estimated a frequency of
positive PCR of 15% (0.78(1–0.8)) after BZN 60d/300 mg
and of 55% (0.78(1–0.3)) after placebo. To preserve 75%
of the BZN 60d/300 mg effect over placebo (40% abso-
lute rate difference), the NI margin will be 10.0%
absolute rate difference. For the 10-month follow-up
aim (Hypothesis 1b), we expect that after almost 1 year,
the PCR positive rates will be up to 20% higher, as
shown in the BENEFIT study [17]. The NI margin pre-
serving 75% of the effect will be 9% in this case. Table 3
shows that we will need to enroll nearly 540 T. cruzi
seropositive women. With this sample size, we will have
adequate power to detect non-inferiority with a NI mar-
gin preserving 75% of the effect of the 60d course over
placebo if the PCR rates following treatment are higher
than expected, or for preserving 70% if a 3% difference
in PCR rates between arms is found. To protect from a
potential 10% loss to follow-up at 10 months, we will en-
roll 600 women.
For Specific Aim 2, we postulated a superiority hy-
pothesis. The rate of serious adverse events leading to
treatment interruption observed in the BENEFIT trial
was 24%. As mentioned above, our population is health-
ier and younger; thus, we will conservatively assume a
20% rate. We will have more than 90% power to detect a
reduction of serious adverse events and/or any adverse
event leading to treatment interruption from 20% in the
60d course group to 10% in the short course group
(Table 4) and more than 80% power if the rate is 12%.
The two-sided Type I error rate was set at α = 0.025 and
0.05 for the NI and superiority hypotheses respectively,
and calculations were carried out with the power sample
size calculator for a two-sample non-inferiority study
with a sampling ratio of one [49].
Interim analysis and study monitoring
The DSMB will be composed of an external peer review
group that will monitor the study enrollment and results
from the study to ensure the safety and ethical treatment
of participants (see DSMB section below for composition
and duties). Membership in the DSMB will consist of
persons completely independent of the investigators who
have no financial, scientific, or other conflict of interest
with the study. The committee will be comprised of an
odd number of members to preclude voting ties. Written
documentation attesting to absence of conflict of interest
will be required. The DSMB will include experts in or
representatives of the fields of:
– Clinical trial methodology and conduct.
– Biostatistics/epidemiology.
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– Clinical medicine.
The overall responsibilities of the DSMB will be to
protect the health and safety of trial participants, to as-
sess the benefits and risks of the trial interventions, and
to monitor the scientific integrity of the study conduct.
The DSMB for this study will act in an advisory capacity
to the PI to monitor patient safety and evaluate the effi-
cacy of the intervention. The initial responsibility of the
DSMB will be to review the protocol to ensure that the
information being collected is sufficient for the DSMB
to monitor study safety and ethical treatment. After this
review and at periodic intervals during the course of the
study, the DSMB responsibilities will be to:
– Review the research protocol, informed consent/
assent documents, and plans for data safety and
monitoring.
– Evaluate the progress of the study, including
periodic assessments of data quality and timeliness,
participant recruitment, accrual and retention,
participant risk versus benefit, performance of the
sites, adverse events, and other factors that can
affect study outcomes.
– Consider factors external to the study when relevant
information becomes available, such as scientific or
therapeutic developments that may have an impact on
the safety of the participants or the ethics of the study.
– Protect the safety of the participants.
– Report on the safety and progress of the study.
– Make written recommendations to the funding agency,
the PI, and, if required, to the involved IRBs concerning
continuation, termination or other modifications of the
study based on the observed beneficial or adverse
effects of any treatment(s) under study, or low
probability of achieving the study objectives.
– Review proposed modifications to the study prior to
their implementation.
– When appropriate, conduct interim analysis of
efficacy in accordance with stopping rules that are
clearly defined in advance of data analysis and have
the approval of the SDC.
– Ensure the confidentiality of the study data and the
results of monitoring.
– Assist National Institute of Health (NIH) by
commenting on any problems with study conduct,
enrollment, and sample size and/or data collection.
– Review any serious issues related to the trial.
Unblinding
The need for unblinding should be extremely rare, as
the adverse events related to BZN may lead to interrup-
tion of treatment but reverse spontaneously [19]. If,
however, unblinding is needed for any reason, the PI will
be informed and Dr. Shaffer will be contacted to reveal
the treatment. Moreover, at the analysis phase, if the
non-inferiority hypothesis is rejected, mothers will be in-
formed of their allocation to the short course or stand-
ard course arm, for discussion with their health
providers. Independently of the outcome of the study, at
the end of the study all women will be informed of their
individual PCR results at 10 months follow-up so that
they may provide this information to their health pro-
viders. The decision to provide this information is the
result of a consensus among investigators and clinicians
from the participating health facilities.
Quality Control (QC) and Quality Assurance (QA)
Overview
A periodic, systematic, and objective validation of the ac-
tivities developed in each site will be implemented by
the Site Data Manager (SDM) and the SDC.
These activities to be completed include:
– To check that all potential eligible women have been
screened. The SDM will compare the screening
forms with the delivery logbook.
– To verify that eligibility criteria have been met. The
SDM will check the forms with the clinical records.
– To verify that all enrolled women signed Consent
Form A at the health facility. For mothers < 16, we
will verify that the women and at least one parent/
guardian have signed Assent Form A and Parental
Consent A. The SDM will monitor a 10–15%
sample of the enrolled women to verify that they
signed the consent/assent form A and were given a
copy.
– To verify that all potential eligible women were
tested for confirmatory T. cruzi serology. The SDM
will verify in the laboratory records the test results
of all women.
– To verify that contact data of all eligible women
who accepted to participate in this stage at health
facility were recorded and kept in a safe location.
– To monitor that all enrolled women are followed up
at 4–8 weeks postpartum and invited to participate.
– To verify that all enrolled women who accepted to
participate signed Consent Form B during the 4–8
weeks follow-up visit. For mothers < 16, we will ver-
ify that the women and at least one parent/guardian
have signed Assent Form B and Parental Consent B.
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The SDM will monitor enrolled women to verify
that they signed the consent/assent form B and were
given a copy.
– To monitor that all enrolled women who accepted
to participate in the trial during 4–8 weeks visit were
followed up at 6 months after delivery and were
randomized.
– To verify that all women have received the clinical
assessment before treatment and were monitored
during treatment and at the end of treatment.
– To check the status of the samples at the laboratory.
The SDM will select the blood samples and will
verify their status at the laboratory (labeling and
storage).
– To check adequate labeling and storage of all the
data collection forms.
– To check that cool chain requirements have been
met.
Selection of study personnel and job descriptions
Site Data Manager
The SDM will have the responsibility of monitoring the
data collection activities, producing the data collection
reports, and performing quality control and quality as-
surance of the data collection process. The data manager
will monitor the health facility data collection activities.
The SDM will monitor the quality in laboratory issues.
Study Field Coordinator
The study field coordinator will be responsible for the
day-to-day operations of the proposed study at each
health facility. She/he will be responsible for the safe
storage of all the materials of the study (CRFs, consent/
assent forms). She/he will also be responsible for the
completion of the corresponding CRFs.
Data Collector
The data collector will be responsible for selecting the
potential eligible women at each health facility, contact-
ing the women, inviting them to participate, and con-
ducting the informed consent process. She/he will be
responsible for completing the corresponding CRFs.
Laboratory Technicians
The laboratory technicians will be responsible for per-
forming the maternal venous blood extractions needed
for confirmatory serologic tests and PCR assay. She/he
will be responsible for collecting DBS for measuring
BZN blood levels. She/he will be responsible for com-
pleting the laboratory data collection forms and solving
any errors that are detected in the CRFs.
Follow-up Coordinator
The follow-up coordinator will be in charge of imple-
menting the follow-up system for women and collecting
pertinent data. She/he will be responsible for inviting
women to participate in the trial and asking the women
to be randomized at 6 months postpartum. She/he will
be responsible for follow-up activities and performing
maternal venous blood extraction before treatment, at
the end of treatment and at 10 months after treatment.
She/he will provide contraceptive methods to the
mothers during treatment. During treatment, she/he will
monitor participants at least once a week for side effects
and adherence and refer the woman to the Clinical Unit
if necessary.
Clinical Unit Director
The clinical unit director in each site will be responsible
for performing the examinations before treatment (EKG,
echocardiogram, chest X-ray, CBC, kidney function tests,
liver function tests, and pregnancy test) and at least once
during treatment (CBC, kidney function tests, liver func-
tion tests, and pregnancy test).
Training procedures
Field personnel will be trained in all the study proce-
dures (see Training study personnel).
On-site monitoring
Monitoring will be carried out through weekly on-site
visits to the participating health facilities by a designated
Data Manager, who will complete weekly reports and
submit them to SDC staff. These staff will hold weekly
monitoring calls with each SDM to discuss site reports
and will produce weekly summary reports, which will be
submitted to the PI and the coordination unit. The SDC
staff will perform at least two site visits per year. During
these visits, source data and biological samples verifica-
tion will be performed in at least 10% of all participants.
Site visits
A site visit by the SDC staff or the PI of the study will
be done at least twice a year. During this site visit the
monitoring and data quality processes will be audited:
– Process forms will be checked.
– Informed consent process will be monitored.
– At least a sample of 10–15% of the CRFs will be
verified on the Clinical and Laboratory records
during the site visit.
– Cool chain requirements of the blood samples will
be checked.
– A sample of blood samples will be checked (amount
of blood, storage, and labeling).
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– Adequate labeling of all data collection forms and
blood samples will be checked.
– Safe storage of the data collection forms will be
checked.
Summary reports
All the QC/QA activities will be reported to the SDC.
The SDC will summarize these data and will submit
them to the PI at Tulane.
Quality control in laboratory testing
External quality assessment
External quality assessment will be performed at the
SPHTM for serology and at the INP (Buenos Aires,
Argentina) or a similar reference laboratory for PCR and
qPCR.
Proficiency testing
Proficiency testing is defined as a reference laboratory
sending unknown samples for testing to a set of labora-
tories. Five blinded panels, containing seronegative hu-
man blood samples spiked with 1, 10, and 100 p/mL of
cultured epimastigotes from CL-Brener (TcVI) T. cruzi
stock and negative controls will be prepared at the INP,
INGEBI, or a similar reference laboratory. Blood samples
will be immediately mixed with one volume of
guanidine-HCl 6M, EDTA 0.2M (pH 8), and, after 48 h
at room temperature, stored at 4 °C until DNA extrac-
tion and PCR/qPCR analysis. Each quality control panel
will be at three-month intervals, covering a period of 1
year at the participating laboratories and the reference
laboratory.
Retesting: retesting refers to samples that have been
analyzed being retested by a reference laboratory, allow-
ing for inter-laboratory comparison. Ten percent of sam-
ples from INGEBI will be sent to the reference
laboratories (SPHTM for serology and INP or a similar
reference laboratory for PCR) to be reanalyzed, using the
same SOPs.
Study organization
Our steering committee includes the PIs, one co-
investigator from the SDC, one co-investigator from
Drugs for Neglected Diseases initiative (DNDi), and one
co-investigator from each of the core laboratories. IECS
will act as the SDC. The proposed study will require 60
months (5 years) to complete, including 24 months for
patient enrollment (Table 5).
Human subjects
The described protocol with informed consent/assent
will be carried out after approval by the IRB of the
Tulane University Health Sciences Center and the IRBs/
ethics committees of the respective collaborating institu-
tions, the University of California at San Diego, and
IECS and Health Policy, Argentina.
Description of participants
We will recruit subjects during 24 months in four health
facilities in Argentina with a total of 23,436 deliveries in
2015. In each participating health facility, we will recruit
not previously treated T. cruzi seropositive women with
a live birth during the postpartum period in Argentina,
randomize them at 6 months postpartum, and follow
them up. We plan to invite 600 T. cruzi seropositive
women of childbearing age to participate, which will in-
clude children in the age range of 13–17.
Participating sites include Hospital J. C. Perrando in
Chaco province, Hospital Regional Dr. Ramón Carrillo
and Centro Integral de Salud La Banda, both in Santiago
del Estero province, and the Instituto de Maternidad y
Ginecología Nuestra Señora de las Mercedes in Tucu-
mán province. The protection of human subjects has
been adequately addressed among the collaborating in-
stitutions at a level that is at least as high as that docu-
mented at the applicant organization, the Tulane
University SPHTM.
Inclusion criteria:
– Written informed consent if 16 or older; for
mothers < 16, we will require written assent and
written consent from at least one parent or
guardian.
– T. cruzi seropositivity confirmed by at least two
positive tests.
– Live birth.
Table 5 Timeline and tasks
Tasks Year 1 Year 2 Year 3 Year 4 Year 5





Data analyses and publications
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Exclusion criteria:
– Women residing outside of the provinces of Chaco,
Santiago del Estero, or Tucumán.
– Previous trypanocide treatment (BZN or
nifurtimox).
– Female sterilization; no intention to use modern
contraception methods during treatment.
– Positive pregnancy test.
– History of severe alcohol abuse within 2 years; renal
insufficiency.
Recruitment
Preventive treatment should be theoretically offered ei-
ther at preconceptional visits or at routine health visits.
However, from a public health perspective, this imple-
mentation plan collides against two barriers: 1) precon-
ceptional visits are not usual practice in Argentina or
other T. cruzi endemic countries in Latin America, and
around half of the pregnancies are unplanned [50]; and
2) screening for T. cruzi infection is not currently stand-
ard practice in women of reproductive age who attend
routine health visits.
There are no publications reporting the number of
women of reproductive age who have received treatment
in Argentina. We have requested this information from
the provincial Chagas centers in the three provinces
where our proposed trial is planned; they have con-
firmed that no systematic records exist and reported that
asymptomatic infected women are very infrequently
treated in the public health sector at the current time.
Treating women during the postpartum period is the
most feasible approach for preconceptional treatment in
Argentina and other endemic countries, because T. cruzi
serological screening is routinely performed during preg-
nancy. Deciding to be treated or not is the single most
important question facing mothers who have found out
they are T. cruzi seropositive during a routine antenatal
screening.
BZN treatment during breastfeeding results in limited
drug transfer into breast milk and seems to have no de-
tectable side effects for the infant [45, 51] but the mater-
nal side effects could cause the interruption of
breastfeeding. This reinforces the importance of testing
a short treatment scheme that might reduce side effects.
Additionally, initiating the treatment at or after 6
months postpartum would be prudent.
Informed consent/assent
Participation in this research is absolutely voluntary.
This study will be conducted following strict guidelines
for the protection of the rights of human volunteers.
The subjects of the study are T. cruzi seropositive
women delivering a live birth at the participating health
facilities. Written informed consent/assent will be ob-
tained immediately after delivery (Consent/Assent A)
and 4–8 weeks postpartum (Consent/Assent B). In-
formed consent/assent forms must be signed by all par-
ticipants. The consent/assent forms will clearly state the
study purpose, eligibility criteria, and protocol of the
study, the potential benefits and risks of participation,
and participants’ rights to refuse to participate or with-
draw from the study.
Consent/assent forms will include the authorization to
participating study institutions to store blood specimens
for up to 10 years for confirmatory studies related to the
primary outcomes, and an opt-out option allowing the
use of stored specimens for other confirmatory studies
(including diagnosis of co-infections) and for potential
human genetic studies linked to mother-to-child trans-
mission of T. cruzi.
Consent/assent forms will also include authorization
to be potentially contacted after the study is over for in-
vitations to participate in potential future studies related
to T. cruzi infection.
Incentives and other benefits
No incentives will be offered to enrolled women. Trans-
portation costs for the participating women will be pro-
vided or reimbursed.
Publications and presentations
The last 10 months of the project will be dedicated to:
1) conducting the data analysis following a previously
prepared data analysis plan; 2) reporting results to par-
ticipating countries, the funding agency, and other stake-
holders; 3) writing and submitting main manuscripts for
publication; and 4) disseminating the findings at selected
scientific or health management meetings.
Discussion
Congenital infection is a major source of T. cruzi infec-
tion, and congenital Chagas disease is associated with se-
vere complications later in life [3]. In consequence of
this, it is important that T. cruzi seropositive women in
reproductive age receive and complete the properly
treatment [14]. However, in most cases adherence to
treatment is difficult to achieve and it is one of the most
common causes that affects its effectiveness.
Particularly in Argentina, the fear of treatment-related
side effects limits the implementation of the Argentine
guideline recommending BZN standard regimen treat-
ment of T. cruzi seropositive women during the postpar-
tum period to prevent transmission in a future
pregnancy [14].
We are proposing to evaluate whether a BZN scheme
with an overall dose of 4.5 g (150 mg daily for 30 days) is
non-inferior to a standard scheme with an overall dose
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of 18 g (300 mg daily for 60 days), a four-fold reduction.
This scheme may work in two ways. First, it has the po-
tential of reducing side effects and treatment interrup-
tions, thus increasing the effectiveness of the treatment
through improving patient compliance. Second, this
lower dose and shorter scheme may have a comparable
trypanocidal effect than the standard scheme. If non-
inferior to the standard scheme, and with fewer side ef-
fects, this short-low dose scheme for preconceptional
treatment of T. cruzi infection would be safer to women,
shorter, and less costly. The results would impact all
women infected by T. cruzi, including the large popula-
tion living in the American countries especially those
women from vulnerable populations who are more af-
fected by the disease.
On the other hand, if this scheme proves to be not in-
ferior to the standard treatment, it will have important
implications for research purposes, installing a lower
limit for the future research of alternative schemes. Also,
this new scheme of treatment could be considered by
the health authorities and be included into the Chagas
disease guideline as a direct public health impact.
Additionally, our focus on the postpartum period is
unique, and, if successful, would provide a feasible solu-
tion to mothers and their health providers. The trial we
are proposing to conduct would be the first controlled
trial comparing alternative BZN schemes among women
of reproductive age. The other current ongoing trials
comparing BZN schemes either do not compare the
same schemes or are not specifically conducted among
women of reproductive age.
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